Canada Markets closed

DiaMedica Therapeutics Inc. (DMA.V)

YHD - YHD Delayed Price. Currency in USD
Add to watchlist
500,000.00+1.16 (+0.00%)
At close: 6:07PM EDT
Sign in to post a message.
  • R
    Ron
    Great buying opportunity today!
  • R
    Ron
    Black Friday Sale!
  • x
    x
    Its green!
  • J
    John
    Falling like a rock. It is horrible.350 trial participants will take FOREVER.
  • J
    John
    At 350 human trial participants it will take DMAC ten years to complete trial. This is an employment contract with management.
  • D
    David
    THIS SHOULD.PRINT 2.75 BY END OF NEXT WEEK....LOL!!!!!!!! ITS OVER
  • R
    Ron
    I find it interesting that people would not want to participate in a trial when their choice is die or try. Remember 80% of people who report stroke symptoms come into the hospitals when it’s too late for existing therapy’s.
  • E
    Elon
    It took 2 years at 12 sites to enroll 91 patients in P2 remedy trial in Australia. If the current trial with 50 sites has similar enrollment rates it will take a year to reach 200 patients.
  • x
    x
    Now they have more odds for an approval. If they miss on the recovery and hit on the recurrence they get the same market potential.
  • c
    chevies
    I’m just holding. They have the product, they have the cash and I believe good things are gonna happen. It may take a little longer than expected, but sometimes you just have to hang in there.
  • C
    Charlie
    They cannot sign up sites.
  • N
    Neil
    took a position Thursday at 4:35 will hold until double digits which will be here by early February 👁️
  • J
    John
    Just getting the 50 sites opened will take two years. Only 1 open now. WOW
  • N
    Neil
    guys really working overtime isn't he... must be something good coming I know it's expirations week volatility reigns supreme across the board.... lay down the caps in the crack pipe man along with the exclamations... take Lexapro it does wonders for mood swings 😜
  • E
    Elon
    From todays abstract: DM199 lowers Gd-IgA1 levels (>20%), the root cause of disease progression and mortality in IgAN patients. These complexes cannot be cleared out of the kidneys because of their large size…an early indication of disease modifying.
    Also encouraging decrease in blood pressure from n hypertensive AA. AUCR decrease was maintained above 30% from baseline with an overall excellent safety profile .
  • E
    Elon
    For IgAN proteinuria reduction (> or equal to 30%) is recognized by FDA as surrogate endpoint for accelerated approval with full approval based on kidney function (eGFR)
  • c
    chevies
    I found some interesting info on KLK1. DM199 is also discussed toward the end. Very favorable

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348491/
  • R
    Rocket man
    David. Take your meds!! Most of us are on here for discussion and information. You just spew venom !!

    Get a hobby. It’s really sad
  • x
    x
    Stroke Statistics
    In 2018, 1 in every 6 deaths from cardiovascular disease was due to stroke.1
    Someone in the United States has a stroke every 40 seconds. Every 4 minutes, someone dies of stroke.2
    Every year, more than 795,000 people in the United States have a stroke. About 610,000 of these are first or new strokes.2
    About 185,000 strokes—nearly 1 of 4—are in people who have had a previous stroke.2
    About 87% of all strokes are ischemic strokes, in which blood flow to the brain is blocked.2
    Stroke-related costs in the United States came to nearly $46 billion between 2014 and 2015.2 This total includes the cost of health care services, medicines to treat stroke, and missed days of work.
    Stroke is a leading cause of serious long-term disability.2 Stroke reduces mobility in more than half of stroke survivors age 65 and over.2

    https://www.cdc.gov/stroke/facts.htm
  • D
    Dave
    Who knows what will happen tomorrow but today, the nutcracker is being best friends with @David